Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma.
In: Immunotherapy Weekly, 2024-02-01, S. 264-264
serialPeriodical
Zugriff:
This article discusses a clinical trial, NCT06209606, that is evaluating the safety and effectiveness of ruxolitinib, steroids, and lenalidomide in patients with progressive multiple myeloma. The trial will use changes in serum B-cell maturation antigen (BCMA) levels to determine disease progression. Preliminary data from the trial shows promising results, with a clinical benefit rate of 46% and an overall response rate of 38%. Another study examined the use of ruxolitinib and steroids in treating relapsed or refractory multiple myeloma, finding positive outcomes. The study also analyzed serum BCMA levels as a predictor of disease progression. The clinical trial is currently recruiting participants and is expected to be completed in February 2029. [Extracted from the article]
Copyright of Immunotherapy Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma.
|
---|---|
Zeitschrift: | Immunotherapy Weekly, 2024-02-01, S. 264-264 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1090-8625 (print) |
Schlagwort: |
|
Sonstiges: |
|